CTOR
Citius Oncology, Inc.1.0700
+0.0200+1.9%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
90.73MP/E (TTM)
-Basic EPS (TTM)
-0.39Dividend Yield
0%Recent Filings
8-K
Positive Phase 1 LYMPHIR combo data
Citius Oncology announced positive topline results from a University of Pittsburgh-led Phase 1 trial on March 10, 2026, testing LYMPHIR combined with pembrolizumab in relapsed/refractory gynecologic cancers. The study in 25 evaluable patients showed no unexpected safety signals, a 24% ORR, and 48% CBR in 21 patients. Full data heads to a cancer conference. Phase 1 wasn't powered for efficacy.
8-K
Positive LYMPHIR Phase 1 CAR-T data
Citius Oncology announced positive topline Phase 1 results on March 4, 2026, for LYMPHIR prior to commercial CAR-T in high-risk relapsed/refractory DLBCL patients. The investigator-initiated trial (n=14) showed 86% ORR, including 57% CR, 77% one-year PFS, and effective Treg depletion with no dose-limiting toxicities. LYMPHIR proved well-tolerated. Study not powered for efficacy conclusions.
8-K
LYMPHIR launch yields $3.9M revenue
10-Q
Q1 FY2026 results
Citius Oncology kicked off LYMPHIR sales in December 2025, posting $3.9M revenue for Q1 FY2026 ended December 31, up from $0 y/y, with 80% gross margin. Operating loss narrowed to $5.3M from $6.4M y/y, yet net loss hit $5.5M versus $6.7M, widened by $4.0M stock-based comp. Diluted EPS improved to -$0.06 from -$0.09 on 87.5M shares. Cash climbed to $7.3M after $15.1M equity raise, funding ops through May 2026; $3.8M related-party note due on $50M financing. License payables linger at $18.3M to Dr. Reddy's. Cash burn persists.
10-K
FY2025 results
Citius Oncology posted a $24.8M net loss for FY2025 ended September 30, 2025, up from $21.1M in FY2024, driven by $6.4M R&D (up from $4.9M) for manufacturing batches and $8.8M G&A (up from $8.1M) tied to LYMPHIR pre-launch. No revenues yet despite FDA approval in August 2024; commercial launch hit December 2025 with initial orders filled then. Cash sat at $3.9M amid $21.9M negative working capital, offset by $15M from equity raises and Citius Pharma funding. Milestone debts loom: $2.9M to Eisai, $19.75M to Dr. Reddy's, plus $21.1M supply commitments. Auditors flag going concern doubts. LYMPHIR may never gain market acceptance.
CBIO
Crescent Biopharma, Inc.
12.92-0.29
CRON
Cronos Group Inc. Common Share
3.16+0.11
CSBR
Champions Oncology, Inc.
6.73-1.14
CTXR
Citius Pharmaceuticals, Inc.
1.10+0.04
CURLF
Curaleaf Holdings, Inc.
4.53+0.85
INCR
Intercure Ltd.
1.45+0.05
LLY
Eli Lilly and Company
1054.29-7.90
NVCR
NovoCure Limited
12.93-0.04
RAPH
RAPHAEL PHARMACEUTICAL INC
1.40+0.00
VREOF
VIREO GROWTH INC.
0.63+0.05